News | May 18, 2021
Sputnik V launch to lift near-term outlook for Dr. Reddy's Labs: HDFC Securities
Dr. Reddy's has the rights to distribute 250mn doses in India
Dr. Reddy's has the rights to distribute 250mn doses in India
India sales grew 23.5% YoY with consolidation of Wockhardt products
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Financial support is being provided as a grant from the Government of India
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Subscribe To Our Newsletter & Stay Updated
